75527-87-6

Basic information

• Product Name: BROMOSULBACTAM
• Synonyms: BROMOSULBACTAM;BrobactaM S,S-Dioxide;Sulbactam EP Impurity C;(2S,5R,6R)-6-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
• CAS NO: 75527-87-6
• Molecular Formula: C₈H₁₀BrNO₅S
• Molecular Weight: 312.139
• Product Categories: Heterocycles;Impurities;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Heterocycles, Impurities, Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals, Sulfur & Selenium Compounds
• Mol File: 75527-87-6.mol

Chemical Properties

• Boiling Point: 596.9±50.0 °C(Predicted)
• Appearance: /
• Density: 1.98±0.1 g/cm3(Predicted)
• PKA: 2.32±0.60(Predicted)
• CAS DataBase Reference: BROMOSULBACTAM(CAS DataBase Reference)
• NIST Chemistry Reference: BROMOSULBACTAM(75527-87-6)
• EPA Substance Registry System: BROMOSULBACTAM(75527-87-6)

Safety Data

• Hazardous Substances Data: 75527-87-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BROMOSULBACTAM is used as an impurity in the production of Sulbactam for its role in the development of antibiotics. The presence of this impurity is significant as it can impact the quality and effectiveness of the final antibiotic product. Ensuring the removal or reduction of BROMOSULBACTAM during the manufacturing process is crucial for maintaining the safety and efficacy of the resulting medication.
As an impurity in the pharmaceutical industry, BROMOSULBACTAM serves as a reminder of the importance of quality control and the need for thorough purification processes in the development of effective and safe medications.

Upstream product

• 76646-91-8 6,6-dibromopenicillanic acid-1,1-dioxide 
• 24138-28-1 6-bromopenicillanic acid 

Downstream Products

• 68373-14-8 sulbactam 

Relevant articles and documents

6-beta-Halopenicillanic acid 1,1-dioxides as beta-lactamase inhibitors

6-beta-Halopenicillanic acid 1,1-dioxides, physiologically acceptable salts thereof and esters thereof readily hydrolyzable; pharmaceutical compositions containing a 6-beta-halopenicillanic acid 1,1-dioxide, a physiologically acceptable salt thereof or an ester thereof readily hydrolyzable; and a method for enhancing the effectiveness of a beta-lactam antibiotic, using a 6-beta-halopenicillanic acid 1,1-dioxide, a physiologically acceptable salt thereof or an ester thereof readily hydrolyzable.

Intermediates for production of 1,1-dioxopenicillanoyloxymethyl 6-(2-amino-2-phenylacetamido)penicillanates

Compounds of the formula STR1 wherein R1 is H or HO; Y and Z are each Cl, Br or I, or Y is H and Z is Cl, Br or I; Q is N3 or NHCO2 CH2 C6 H4 R4 where R4 is H, Cl, Br,

6-Alpha-halopenicillanic acid 1,1-dioxides

A process for the preparation of penicillanic acid 1,1-dioxide and esters thereof readily hydrolyzable in vivo, which comprises oxidation of a 6-halopenicillanic acid, or an ester thereof readily hydrolyzable in vivo, to the corresponding 6-halopenicillanic acid 1,1-dioxide or ester thereof, followed by dehalogenation (e.g. by hydrogenolysis). Certain of the 6-halopenicillanic acid 1,1-dioxides and esters thereof readily hydrolyzable in vivo are novel intermediates. Penicillanic acid 1,1-dioxide, and esters thereof readily hydrolyzable in vivo are known compounds which are beta-lactamase inhibitors and which enhance the effectiveness of certain beta-lactam antibiotics (e.g. the penicillins) in the treatment of bacterial infections in mammals, particularly humans.

Preparation of halomethyl esters (and related esters) of penicillanic acid 1,1-dioxide

Process for preparation of halomethyl esters (and related esters) of penicillanic acid 1,1-dioxide of the formula STR1 where X is Cl, Br, I, certain alkylsulfonyloxy or arylsulfonyloxy groups, useful as intermediates in production of antibiotics having beta-lactamase activity, which comprises hydrogenolysis of an ester of the formula STR2 where n is zero, 1 or 2; Y and Z are each Cl, Br or I, or Y is H and Z is Cl, Br, I, C N-- or SCN--, or Y is arylselenyl and Z is Cl or Br; and when n is zero or 1, oxidation of the hydrogenolysis product; a process for preparing compounds of formula (VI, n=2) by oxidation of the corresponding compound (VI) wherein n is zero or 1, and certain novel intermediates useful in the above processes.

6α-Bromopenicillanic acid sulfone

(2S,5R,6S)-6α-Bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, S,S-dioxide, physiologically acceptable salts thereof and readily hydrolyzable ester thereof inhibit the action of the β-lactamase enzyme RTEM.